Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Yuqing ZhangXiaoxin ZhangLifan LinMingzhao XingPublished in: The Journal of clinical endocrinology and metabolism (2024)
The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes and the new drug apatinib demonstrates promise for potentially superior performance.